반응식
[NH:1]1[CH:5]=[C:4]([C:6]2[N:11]=[C:10]3[N:12]([CH2:15][C:16]4[CH:17]=[C:18]5[C:23](=[CH:24][CH:25]=4)[N:22]=[CH:21][CH:20]=[CH:19]5)[N:13]=[N:14][C:9]3=[N:8][CH:7]=2)[CH:3]=[N:2]1.C([O-])([O-])=O.[Cs+].[Cs+].[CH3:32][C:33]1([CH3:36])[CH2:35][O:34]1>CN(C=O)C>[CH3:32][C:33]([OH:34])([CH3:36])[CH2:35][N:2]1[CH:3]=[C:4]([C:6]2[N:11]=[C:10]3[N:12]([CH2:15][C:16]4[CH:17]=[C:18]5[C:23](=[CH:24][CH:25]=4)[N:22]=[CH:21][CH:20]=[CH:19]5)[N:13]=[N:14][C:9]3=[N:8][CH:7]=2)[CH:5]=[N:1]1참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
반응 조건
- 온도
- 80 °C
실험 절차
To a suspension of 6-[6-(1H-pyrazol-4-yl)-[1,2,3]triazolo[4,5-b]pyrazin-1-ylmethyl]-quinoline (50 mg, 0.15 mmol) and Cs2CO3 (50 mg, 0.15 mmol) in DMF (2 mL) was added 2,2-dimethyl-oxirane. The reaction was stirred at 80° C. for 16 hours. The reaction was then purified with a reverse-phased preparative HPLC eluting with acetonitrile-water having 0.1% acetic acid to yield 2-methyl-1-[4-(3-quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-propan-2-ol (13 mg, 22% yield).
후처리
- customThe reaction was then purified with a reverse-phased preparative HPLC
- washeluting with acetonitrile-water having 0.1% acetic acid
출처 및 근거
- ORD 기록
- ord-fdda75a4549845cc8f7d28aa5e280eb8
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07732604B2
연결된 노트
불러오는 중…